ESTOPAUSE Film Coated Tablet
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
21-03-2023
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
ESTRADIOL ESTRADIOL MEDROXYPROGESTERONE ACETATE
Available from:
Resource Medical (UK) Limited
Pharmaceutical form:
Film Coated Tablet
Authorization date:
2008-03-07
Summary of Product characteristics
License
Part II
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
Estopause Film-coated Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each white tablet contains 2 mg of Oestradiol. Each pale blue tablet contains 2 mg of Oestradiol and 5 mg of
Medroxyprogesterone Acetate.
For excipients see 6.1.
3 PHARMACEUTICAL FORM
Film-coated tablet.
Calendar pack consisting of 16 round, white, biconvex tablets and 12 round, pale-blue, biconvex tablets.
4 CLINICAL PARTICULARS
4.1 Therapeutic Indications
Hormone replacement therapy (HRT) for estrogen deficiency symptoms. In post menopausal women with an
intact uterus.
Second line therapy for prevention of osteoporosis in postmenopausal women at high risk of future fractures who
are intolerant of, or contraindicated for , other medicinal products approved for the prevention of osteoporosis.
The experience of treating women older than 65 years is limited.
4.2 Posology and method of administration
Adults and elderly
Estopause is a continuous sequential combined HRT regimen (Oestrogen and Medroxyprogesterone). The
oestrogen phase (2mg oestrogen [17
oestradol] is given for the first 16 days. This is followed by a combined
oestrogen and progesterone acetate for 12 days.
The regimen is
Read the complete document
